Literature DB >> 8446138

Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

B J Materson1, D J Reda, W C Cushman, B M Massie, E D Freis, M S Kochar, R J Hamburger, C Fye, R Lakshman, J Gottdiener.   

Abstract

BACKGROUND: Characteristics such as age and race are often cited as determinants of the response of blood pressure to specific antihypertensive agents, but this clinically important issue has not been examined in sufficiently large trials, involving all standard treatments, to determine the effect of such factors.
METHODS: In a randomized, double-blind study at 15 clinics, we assigned 1292 men with diastolic blood pressures of 95 to 109 mm Hg, after a placebo washout period, to receive placebo or one of six drugs: hydrochlorothiazide (12.5 to 50 mg per day), atenolol (25 to 100 mg per day), captopril (25 to 100 mg per day), clonidine (0.2 to 0.6 mg per day), a sustained-release preparation of diltiazem (120 to 360 mg per day), or prazosin (4 to 20 mg per day). The drug doses were titrated to a goal of less than 90 mm Hg for maximal diastolic pressure, and the patients continued to receive therapy for at least one year.
RESULTS: The mean (+/- SD) age of the randomized patients was 59 +/- 10 years, and 48 percent were black. The average blood pressure at base line was 152 +/- 14/99 +/- 3 mm Hg. Diltiazem therapy had the highest rate of success: 59 percent of the treated patients had reached the blood-pressure goal at the end of the titration phase and had a diastolic blood pressure of less than 95 mm Hg at one year. Atenolol was successful by this definition in 51 percent of the patients, clonidine in 50 percent, hydrochlorothiazide in 46 percent, captopril in 42 percent, and prazosin in 42 percent; all these agents were superior to placebo (success rate, 25 percent). Diltiazem ranked first for younger blacks (< 60 years) and older blacks (> or = 60 years), among whom the success rate was 64 percent, captopril for younger whites (success rate, 55 percent), and atenolol for older whites (68 percent). Drug intolerance was more frequent with clonidine (14 percent) and prazosin (12 percent) than with the other drugs.
CONCLUSIONS: Among men, race and age have an important effect on the response to single-drug therapy for hypertension. In addition to cost and quality of life, these factors should be considered in the initial choice of a drug.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8446138     DOI: 10.1056/NEJM199304013281303

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  267 in total

1.  Beta-blockers as first-line therapy for hypertension.

Authors:  G A Heckman; A Papaioannou; W Parkinson; C A Patterson
Journal:  CMAJ       Date:  2000-11-28       Impact factor: 8.262

2.  Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association.

Authors: 
Journal:  Heart       Date:  1998-12       Impact factor: 5.994

Review 3.  Observational studies of antihypertensive medication use and compliance: is drug choice a factor in treatment adherence?

Authors:  K A Payne; S Esmonde-White
Journal:  Curr Hypertens Rep       Date:  2000-12       Impact factor: 5.369

4.  New Canadian hypertension recommendations. So what?

Authors:  N R Campbell
Journal:  Can Fam Physician       Date:  2000-07       Impact factor: 3.275

5.  Clinical trials report. The effect of Ramipril versus Amlodipine on renal outcomes in hypertension nephrosclerosis.

Authors:  D G Vidt
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

Review 6.  Use of gene markers to guide antihypertensive therapy.

Authors:  S T Turner; G L Schwartz; A B Chapman; E Boerwinkle
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

Review 7.  Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension.

Authors:  M Ruzicka; F H Leenen
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 8.  Matching the right drug to the right patient in essential hypertension.

Authors:  M J Brown
Journal:  Heart       Date:  2001-07       Impact factor: 5.994

9.  Problems in the control of systolic blood pressure.

Authors:  L M Ruilope
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

Review 10.  What are the elements of good treatment for hypertension?

Authors:  C D Mulrow; M Pignone
Journal:  BMJ       Date:  2001-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.